CureVac Full Year 2023 Earnings: Misses Expectations
Yahoo FinanceApr 27 08:33 ET
Express News | CureVac NV : UBS Cuts Target Price to $14 From $18
ReutersApr 26 10:32 ET
Curevac's Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
TipRanksApr 26 02:01 ET
Express News | CureVac Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $12 to $4
BenzingaApr 25 11:29 ET
CureVac Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 60% Leerink Partners $12 → $4 Downgrades Outperform → Market Perform 04/05/2024 — Guggenheim R
BenzingaApr 25 09:10 ET
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
TipRanksApr 25 07:51 ET
Express News | CureVac NV : Leerink Partners Cuts Target Price to $4 From $12
ReutersApr 25 07:18 ET
Express News | CureVac NV : Leerink Partners Cuts to Market Perform From Outperform
ReutersApr 25 07:18 ET
Earnings Call Summary | CureVac(CVAC.US) Q4 2023 Earnings Conference
The following is a summary of the CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript:Financial Performance:CureVac reported solid cash position of €402.5 million at the end of 2023 and expects to ex
moomoo AIApr 24 19:56 ET · Conference Call
CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
TipRanksApr 24 17:30 ET
CureVac Launches Study for H5N1 Influenza Vaccine
TipRanksApr 24 17:29 ET
CureVac Names New Chief Business Officer
TipRanksApr 24 17:28 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and CureVac (CVAC)
TipRanksApr 24 16:30 ET
CureVac Shares Touch All-Time Low After Germany Deal Ends, Redesign News
By Stephen Nakrosis Shares of biopharmaceutical company CureVac touched a new low on Wednesday following news the company, together with GSK, ended a pandemic agreement with Germany and will implemen
WSJApr 24 14:03 ET
CureVac Begins Early Stage Portion of Investigational Vaccine Trial
CureVac (CVAC) said Wednesday it initiated the early stage portion of a broader study into an investigational flu vaccine developed with GSK (GSK). The phase 1 trial is part of a combined phase 1/2 st
MT NewswiresApr 24 12:27 ET
CureVac Hires New Chief Business Officer
German biopharmaceutical company CureVac (5CV.F) named Thaminda Ramanayake its new chief business officer, effective June 1. Ramanayake recently served as Affini-T Therapeutics' business chief, accord
MT NewswiresApr 24 10:46 ET
Express News | CureVac Shares Are Trading Lower After the Company Reported Q4 Financial Results and Provided Business Updates
Moomoo 24/7Apr 24 10:35 ET
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M
08:01 AM EDT, 04/24/2024 (MT Newswires) -- Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M
MT NewswiresApr 24 08:01 ET
CureVac BV Reports Q4 Results
Seeking AlphaApr 24 07:30 ET
Express News | CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus
Moomoo 24/7Apr 24 07:20 ET
No Data
No Data